文献速递头颈外科

局部晚期头颈癌接受根治性放疗联合同期西妥昔单抗的总生存期下降:美国国家癌症数据库分析

Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis.
PubMed 文献 · Head Neck · 2022-04-07

基于美国国家癌症数据库2013至2016年数据,比较III-IVB期头颈鳞癌患者接受单纯放疗、放化疗或放疗联合西妥昔单抗的总生存期。共31014例患者,2年OS分别为单纯放疗69%、放化疗79%、西妥昔单抗联合放疗66%(p<0.001);在整体和倾向匹配队列中,放化疗和单纯放疗均与较西妥昔单抗联合放疗改善的OS相关(p≤0.001)。结论认为西妥昔单抗联合放疗与OS下降相关,提示该人群生物放疗获益甚微。

要点

  • 31014例III-IVB期头颈鳞癌中,放化疗占72%,单纯放疗占22%,西妥昔单抗联合放疗占6%。
  • 2年OS:放化疗79% vs 单纯放疗69% vs 西妥昔单抗联合放疗66%(p<0.001)。
  • 整体和倾向匹配队列中,放化疗和单纯放疗均与较西妥昔单抗联合放疗改善的OS相关(p≤0.001)。

核心结论

  • 与放化疗或单纯放疗相比,西妥昔单抗联合放疗与头颈鳞癌患者总生存期下降相关,提示该人群生物放疗获益甚微。

研究设计与样本

  • 基于美国国家癌症数据库的回顾性分析,纳入2013至2016年接受治疗的III-IVB期头颈鳞癌患者31014例。
  • 比较单纯放疗(22%)、放化疗(72%)和西妥昔单抗联合放疗(6%)三组,采用Cox比例风险模型估计总生存期,并在整体队列和倾向匹配队列中分析。

主要发现

  • 2年总生存率:单纯放疗组69%,放化疗组79%,西妥昔单抗联合放疗组66%(p<0.001)。
  • 在整体队列和倾向匹配队列中,放化疗和单纯放疗均与较西妥昔单抗联合放疗改善的总生存期相关(p≤0.001)。

临床怎么用

  • 原文结论认为,与放化疗或单纯放疗相比,西妥昔单抗联合放疗与总生存期下降相关,提示该人群生物放疗获益甚微。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recently, randomized trials have questioned the efficacy of cetuximab-based bioradiotherapy compared to chemoradiation for patients with squamous cell carcinoma of the oropharynx, larynx, and hypopharynx (HNSCC). We compared the OS of patients treated with radiotherapy alone (RTonly), chemoradiotherapy (chemoRT), and bioradiotherapy (cetuxRT). METHODS: Patients with stage III-IVB HNSCC treated with RTonly, chemoRT, or cetuxRT were identified in the National Cancer Database. OS was estimated using Cox proportional hazards. Analyses were conducted on the overall cohort and propensity matched cohorts. RESULTS: 31 014 patients were treated with RTonly (22%), chemoRT (72%), or cetuxRT (6%) from 2013 to 2016. The 2-year OS was 69% for RTonly, 79% for chemoRT, and 66% for cetuxRT (p < 0.001). In the overall and propensity-matched cohorts, chemoRT and RTonly were associated with improved OS as compared to cetuxRT (p ≤ 0.001). CONCLUSION: Compared to chemoRT or RTonly, cetuxRT is associated with decreased OS for patients with HNSCC, suggesting minimal benefit of bioradiotherapy in this population.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Korpics MC, Turchan WT, Koshy M, et al. Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis. Head Neck. 2022. PMID: 35393753. doi:10.1002/hed.27050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。